Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Clinico-Hematological Profile of Patients with B-Chronic Lymphoid Leukemia in Pakistan

  • Zeeshan, Rozina (Hematology Department, Hematology & Blood Bank, Liaquat National Hospital and Medical College) ;
  • Sultan, Sadia (Hematology Department, Hematology & Blood Bank, Liaquat National Hospital and Medical College) ;
  • Irfan, Syed Muhammad (Hematology Department, Hematology & Blood Bank, Liaquat National Hospital and Medical College) ;
  • Kakar, Jamaludin (Hematology Department, Hematology & Blood Bank, Liaquat National Hospital and Medical College) ;
  • Hameed, Muhammad Asif (Hematology Department, Hematology & Blood Bank, Liaquat National Hospital and Medical College)
  • Published : 2015.02.25
Download PDF
⟨ Previous Next ⟩

Abstract

Background: Chronic lymphoid leukemia (CLL) is not an uncommon hematological malignancy which primarily affects elderly individuals. It is more common in developed world than in developing countries. The rational of this study was to determine the clinico-hematological profile in Pakistan. Materials and Methods: In this prospective cross sectional study, sixty patients with CLL were enrolled from January 2011 to June 2013. Data were analyzed with SPSS version 21. Results: The mean age was $59.0{\pm}9.2years$ (range 40-82) and the male to female ratio was 2.1:1. Peak age group was 60-70 years (38.3%) and 18.3% were under 50 years old. Major complaints were weakness (51.7%), fever (18.3%) and abdominal discomfort (13.3%). Main clinical findings were splenomegaly (46.6%), lymphadenopathy (36.6%) and pallor (26.7%). Some 16.7% were diagnosed incidentally. The mean hemoglobin was $10.8{\pm}2.4g/dl$, with a total leukocyte count of $91.5{\pm}87.8{\times}10^9/l$ and platelets $197.8{\pm}103.2{\times}10^9/l$. Anemia and thrombocytopenia were seen in 26.7% and 21.7% of cases, respectively. High LDH and hyperuricemia were detected in 15% each and elevated serum creatinine was seen in 11.6%. According to Rai staging 11.6% were in stage 0, 13.3% stage 1, 26.7% each for stage II and stage III while 21.7% patients were in stage IV. Conclusions: CLL in our patients in Pakistan, unlike in the West, is seen in a relatively young population with male predominance. Primarily disease is of B-cell origin and about 2/3 of the patients present at advanced stage.

Keywords

References

  1. Agrawal N, Naithani R, Mahapatra M, et al (2007). Chronic lymphocytic leukemia in India - a clinico-haematological profile. Hematology, 12, 229-33. https://doi.org/10.1080/10245330701255064
  2. D'Arena G, Tarnani M, Rumi C, et al (2007). Prognostic significance of combined analysis of ZAP-70 and CD38 in chronic lymphocytic leukemia. Am J Hematol, 82, 787-91. https://doi.org/10.1002/ajh.20936
  3. Dodhy MA, Zafar H, Aslam W (2011). Chronic Lymphocytic Leukemia: an Experience of a decade at a Tertiary Care Hospital. Ann Pak Inst Med Sci, 7, 196-9.
  4. Ehsan A, Lone A, Khan MA (2013). Autoimmune complications in chronic lymphocytic leukemia: a single center experience. Biomedica, 29, 37-41.
  5. Ghosh J, Singh RK, Saxena R, et al (2013). Prevalence and aetiology of anaemia in lymphoid malignancies. Natl Med J India, 26, 79-81.
  6. Gogia, A. Sharma, V. Raina, et al (2011). Clinico-hematological characteristics and outcome assessment of patients with chronic lymphocytic leukemia. J Clin Oncol, 29, 2011. https://doi.org/10.1200/JCO.2010.33.5091
  7. Gribben JG (2008). Molecular profiling in CLL. Hematology Am Soc Hematol Educ Program. 2008, 444-9. https://doi.org/10.1182/asheducation-2008.1.444
  8. Hamblin TJ (2007). Prognostic markers in chronic lymphocytic leukaemia. Best Pract Res Clin Haematol, 20, 455-68. https://doi.org/10.1016/j.beha.2007.02.001
  9. Idris M, Shah SH, Fareed J, Gul N (2004). An experience with sixty cases of haematological malignancies; a clinico haematological correlation. J Ayub Med Coll Abbottabad, 16, 51-4.
  10. Kawamata N, Moreilhon C, Saitoh T, et al (2013). Genetic differences between Asian and Caucasian chronic lymphocytic leukemia. Int J Oncol, 43, 561-5.
  11. Kermani IA, Dehdilani M, Dolatkhah R (2007). Chronic lymphocytic leukemia in the recent 10 years and treatment effects of fludarabin. Asian Pac J Cancer Prev, 8, 367-71.
  12. Khan M, Saif A, Sandler S, Mirrakhimov AE (2014). Idelalisib for the treatment of chronic lymphocytic leukemia. ISRN Oncol, 2014, 931858.
  13. Khalid A, Zahid M, Rehman A, et al (1997). Clinicoepidemiological features of adult leukemias in Pakistan. Pak Med Assoc, 47, 119-22.
  14. Li ZJ, Qiu LG, Wu T, et al (2008). The clinical and laboratory features of 263 cases of chronic lymphocytic leukemia. Zhonghua Xue Ye Xue Za Zhi, 29, 300-3.
  15. Maurer C, Hallek M (2013). Chronic lymphocytic leukemia. Dtsch Med Wochenschr, 138, 2153-66. https://doi.org/10.1055/s-0033-1349491
  16. Mozaheb Z, Hasanzadeh NazarAbadi MH, Aghaee MA (2012). Chronic lymphocytic leukemia and prognostic factors. Asian Pac J Cancer Prev, 13, 3009-13. https://doi.org/10.7314/APJCP.2012.13.7.3009
  17. Mukiibi JM, Paul B, Nyirenda CM, et al (2004). Chronic lymphocytic leukaemia (CLL) in Central Africans. Cent Afr J Med, 50, 111-5.
  18. Omoti CE, Awodu OA, Bazuaye GN (2007).Chronic lymphoid leukaemia: clinico-haematological correlation and outcome in a single institution in Niger Delta region of Nigeria. Int J Lab Hematol, 29, 426-32. https://doi.org/10.1111/j.1751-553X.2007.00888.x
  19. Qi RJ, Zhang PH, Qiu LG, et al (2009). Clinical significance of ZAP-70 protein expression in chronic lymphocytic leukemia/small lymphocytic lymphoma. Zhonghua Bing Li Xue Za Zhi, 38, 329-32.
  20. Rafiq N, Iqbal T, Shahid M, Muhammad F (2014). Hematological and biochemical parameters in Pakistani chronic lymphoblastic leukemia patients. Pak J Life Soc Sci, 12, 16-19.
  21. Redaelli A, Laskin BL, Stephens JM, Botteman MF, Pashos CL (2004). The clinical and epidemiological burden of chronic lymphocytic leukaemia. Eur J Cancer Care Engl, 13, 279-87. https://doi.org/10.1111/j.1365-2354.2004.00489.x
  22. Sagatys EM, Zhang L (2012). Clinical and laboratory prognostic indicators in chronic lymphocytic leukemia. Cancer Control, 19, 18-25.
  23. Salawu L, Bolarinwa RA, Durosinmi MA (2010). Chronic lymphocytic leukaemia: a-twenty-years experience and problems in Ile-Ife, South-Western Nigeria. Afr Health Sci, 10, 187-92.
  24. Sriphatphiriyakun T, Auewarakul CU (2005). Clinical presentation and outcome of Thai patients with chronic lymphocytic leukemia: retrospective analysis of 184 cases. Asian Pac J Allergy Immunol, 23, 197-203.
  25. Tjonnfjord GE, Ly BE, Johannesen TB, et al (2012). Chronic lymphocytic leukaemia in Norway--incidence and prognostic markers at diagnosis. Tidsskr Nor Laegeforen, 132, 2056-9. https://doi.org/10.4045/tidsskr.11.1349
  26. Vroblova V, Smolej L, Vrbacky F, et al (2009). Biological prognostic markers in chronic lymphocytic leukemia. Acta Medica Hradec Kralove, 52, 3-8.

Cited by

  1. Suppression of HSP27 increases the anti-tumor effects of quercetin in human leukemia U937 cells vol.13, pp.1, 2015, https://doi.org/10.3892/mmr.2015.4600
  2. Serum 25-hydroxyvitamin D Insufficiency in B-Chronic Lymphoid Leukemia at the Time of Disease Presentation in Pakistan vol.16, pp.14, 2015, https://doi.org/10.7314/APJCP.2015.16.14.5983
  3. Direct Coombs Test Positivity in B-Chronic Lymphoid Leukemia: a Marker of Advanced Clinical Disease vol.16, pp.14, 2015, https://doi.org/10.7314/APJCP.2015.16.14.6007